Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL. clonoSEQ is the only DLBCL MRD assay available for clinical u ...

Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS ...

Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point? The following represents disclosure information provided ...

Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in ...

Ibrutinib, a BTK inhibitor, is effective in treating relapsed CLL, with combination therapies improving response rates. Combination therapy with ibrutinib and venetoclax, guided by MRD ...

Concerning overall survival and disease control, no disadvantage compared to other populations of CLL patients receiving immuno-chemotherapy could be detected, as a mortality rate of 4% and median ...

Targeted therapies treat chronic lymphocytic leukemia at the molecular level. BTK inhibitors, P13K inhibitors, monoclonal antibodies, and BCL2 agonists are types of targeted therapy for CLL that ...

Patients with undetectable MRD at landmark and longitudinal time points had significantly longer disease-free survival than patients who had detectable MRD at those time points. Prolonged ...

A-CLL is distinguished by its intermediate behavior between indolent ... achieving a partial response (PR) with some residual lymph nodes measuring 2 cm and detectable minimal residual disease (MRD4, ...

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are very similar because they have the same type of ...